Recent update on anti-dengue drug discovery

• Published in: European journal of medicinal chemistry Vol. 176; pp. 431 - 455
• Main Authors: Dighe, Satish N., Ekwudu, O'mezie, Dua, Kamal, Chellappan, Dinesh Kumar, Katavic, Peter L., Collet, Trudi A.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 15.08.2019
• Subjects: Dengue; DENV; HTS; HTVS; Natural product; NS3; NS4; NS5; Synthesis; NS5; Synthesis; Dengue; DENV; HTS; Natural product; HTVS; NS4; NS3
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2019.05.010

Dengue is the most important arthropod-borne viral disease of humans, with more than half of the global population living in at-risk areas. Despite the negative impact on public health, there are no antiviral therapies available, and the only licensed vaccine, Dengvaxia®, has been contraindicated in children below nine years of age. In an effort to combat dengue, several small molecules have entered into human clinical trials. Here, we review anti-DENV molecules and their drug targets that have been published within the past five years (2014–2018). Further, we discuss their probable mechanisms of action and describe a role for classes of clinically approved drugs and also an unclassified class of anti-DENV agents. This review aims to enhance our understanding of novel agents and their cognate targets in furthering innovations in the use of small molecules for dengue drug therapies. [Display omitted] •Drug targets important for anti-dengue drug discovery have been briefly discussed.•Anti-dengue compounds reported in the last five years are discussed.•Anti-dengue activity of other classes of clinically approved drugs is provided.